Lightstone Ventures is a global venture capital firm founded in 2012, focusing on biotech and medtech companies that are pioneering transformative therapies and technologies. The firm typically invests in Series A through Series E rounds, with a strong emphasis on translating novel scientific breakthroughs into clinically and commercially meaningful outcomes. Lightstone Ventures partners with visionary entrepreneurs to provide the necessary resources and operational guidance to bring innovative therapeutics to market.
Notable portfolio companies include Nimbus Therapeutics, which has raised $443 million, Earlens with $234 million, and Relievant Medsystems with $178 million. Key partners at Lightstone Ventures include Hong I. Wan, Karun D. Naga from The Foundry, LLC, Susan Molineaux of Calithera Biosciences, Adam D. Gridley from Allay Therapeutics, and Jaume Pons of ALX Oncology. The firm prides itself on being partners, collaborators, and mentors, offering a broad commitment to improving patient outcomes through disruptive technologies.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.
